{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:53:34Z","timestamp":1785920014626,"version":"3.56.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:02:18Z","timestamp":1596286938000},"page":"903-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"David A.","family":"Bond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2020.06.007_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2020.06.007_bib3","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.hoc.2020.06.007_bib4","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.007_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.007_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10020","key":"10.1016\/j.hoc.2020.06.007_bib7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.007_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.007_bib9","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.hoc.2020.06.007_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A\u00a0role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib11","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.007_bib12","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in\u00a0vivo","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.007_bib13","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.007_bib14","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.007_bib15","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.hoc.2020.06.007_bib16","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin alphaIIbbeta3 in mice and humans","volume":"3","author":"Dobie","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib19","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.hoc.2020.06.007_bib20","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib21","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","article-title":"Ibrutinib-associated ventricular arrhythmia in the FDA adverse event reporting system","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.007_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.007_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jacep.2016.07.004","article-title":"Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia","volume":"2","author":"Tomcsanyi","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ccr3.719","article-title":"A\u00a0case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma","volume":"4","author":"Wallace","year":"2016","journal-title":"Clin Case Rep"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib25","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jemermed.2016.10.019","article-title":"A\u00a0perfect storm: tyrosine kinase inhibitor-associated polymorphic ventricular tachycardia","volume":"52","author":"Beyer","year":"2017","journal-title":"J\u00a0Emerg Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.06.007_bib26","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2020.06.007_bib27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.007_bib28","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.007_bib30","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10121","key":"10.1016\/j.hoc.2020.06.007_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.007_bib32","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.007_bib33","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.007_bib34","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.007_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.06.007_bib36","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2018-99-117224","article-title":"Updated safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma","volume":"132","author":"Tam","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.06.007_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","article-title":"Safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A\u00a0phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.007_bib39","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","article-title":"Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059)","volume":"34","author":"Rule","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.007_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2019-126305","article-title":"Safety and efficacy of orelabrutinib monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study","volume":"134","author":"Song","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib41","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"24","key":"10.1016\/j.hoc.2020.06.007_bib42","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2020.06.007_bib43","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.007_bib44","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.06.007_bib45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.007_bib46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib48","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib50","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.06.007_bib51","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2019-126286","article-title":"Ongoing results of a phase 1B\/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.007_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2019-127509","article-title":"Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.007_bib53","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \"real world\" study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.007_bib55","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.007_bib56","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.14669","article-title":"Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma","volume":"181","author":"Srour","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.007_bib59","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib60","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1002\/ajh.25278","article-title":"Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma","volume":"93","author":"Tisi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.06.007_bib61","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood-2019-129829","article-title":"R-BAC maintains high response rate in mantle cell lymphoma following relapse on BTK inhibitor therapy","volume":"134","author":"McCulloch","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.007_bib62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.007_bib63","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.007_bib64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2019-126064","article-title":"KTE-X19, an anti-CD19 chimeric antigen receptor T\u00a0cell therapy, in patients with relapsed\/refractory mantle cell lymphoma: results of the phase 2 ZUMA-2 study","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.007_bib65","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.007_bib68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib69","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib71","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.007_bib72","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","article-title":"The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in\u00a0vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies","volume":"102","author":"Golay","year":"2017","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.hoc.2020.06.007_bib73","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell Non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.hoc.2020.06.007_bib74","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.007_bib75","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.007_bib76","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.007_bib77","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.007_bib78","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.007_bib79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.007_bib80","doi-asserted-by":"crossref","first-page":"622","DOI":"10.18632\/oncotarget.938","article-title":"Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms","volume":"4","author":"Axelrod","year":"2013","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.007_bib81","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"issue":"48","key":"10.1016\/j.hoc.2020.06.007_bib82","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/onc.2016.155","article-title":"FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.007_bib83","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.007_bib84","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","article-title":"Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.007_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.06.007_bib86","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2019-128788","article-title":"Multi-institution phase I\/Ib continual re-assessment study to identify the optimal dose of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma","volume":"134","author":"Portell","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2020.06.007_bib87","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.007_bib88","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2019.1612062","article-title":"A\u00a0phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma","volume":"60","author":"Martin","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.007_bib89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A\u00a0phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.007_bib90","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A\u00a0phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.06.007_bib91","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2018-99-110617","article-title":"Safety and efficacy of acalabrutinib plus bendamustine and rituximab (BR) in patients with treatment-naive (TN) or relapsed\/refractory (R\/R) mantle cell lymphoma (MCL)","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.007_bib92","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2019-122191","article-title":"Efficacy and safety of ibrutinib in combination with rituximab as frontline treatment for indolent clinical forms of mantle cell lymphoma: preliminary results of geltamo IMCL-2015 phase II trial","volume":"134","author":"Gine","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.007_bib93","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2019-125800","article-title":"Frontline treatment with ibrutinib with rituximab (IR) combination is highly effective in elderly patients with mantle cell lymphoma - results from a phase II trial","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.007_bib94","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood-2019-126044","article-title":"Frontline treatment with ibrutinib plus rituximab followed by short course R-hypercvad\/MTX is extremely potent and safe in patients with mantle cell lymphoma - results of phase-II window-1 clinical trial","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.007_bib95","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.007_bib96","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:29Z","timestamp":1760184869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300708"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}